Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 9/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26435665 | 1.00 | CRBN (0.48) | CRBNGSPT1DDB1CCNCCDK8 | |
| SCHEMBL26089671 | 1.00 | CRBN (0.48) | CRBNGSPT1DDB1CCNCCDK8 | |
| SCHEMBL26089304 | 0.89 | CRBN (0.51) | CRBNGSPT1DDB1CNR1CNR2 | |
| SCHEMBL30349500 | 0.89 | CRBN (0.51) | CRBNGSPT1DDB1CNR1CNR2 | |
| SCHEMBL26087813 | 0.89 | CRBN (0.46) | CRBNGSPT1DDB1CNR1CNR2 | |
| SCHEMBL30349540 | 0.89 | CRBN (0.46) | CRBNGSPT1DDB1CNR1CNR2 | |
| SCHEMBL26435065 | 0.88 | CRBN (0.47) | CRBNGSPT1DDB1CNR1CNR2 | |
| SCHEMBL30407784 | 0.88 | EPHX2 (0.44) | CRBNGSPT1DDB1EPHX2 | |
| SCHEMBL26087477 | 0.88 | EPHX2 (0.44) | CRBNGSPT1DDB1EPHX2 | |
| SCHEMBL30408206 | 0.84 | CRBN (0.36) | CRBNGSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | CRBN 1/4885GSPT1 2/4885DDB1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.